Everest Medicines (HKSE:01952) Momentum Rank : 9 (As of May. 29, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Everest Medicines Momentum Rank?

Everest Medicines has the Momentum Rank of 9.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Everest Medicines's Momentum Rank

For the Biotechnology subindustry, Everest Medicines's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Everest Medicines's Momentum Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Everest Medicines's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Everest Medicines's Momentum Rank falls into.

Everest Medicines Momentum Rank Related Terms

Thank you for viewing the detailed overview of Everest Medicines's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Everest Medicines (HKSE:01952) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

6HN:Germany

Address

1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041

Website

https://www.everestmedicines.com

Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.

Executives

Fu Wei	2307 Founder of a discretionary trust who can infl
Nova Aqua Limited	2201 Interest of corporation controlled by you
C-bridge Joint Value Creation Limited	2201 Interest of corporation controlled by you
Everest Management Holding Co., Ltd.	2101 Beneficial owner
Ra Capital Management, L.p.	2102 Investment manager
Kolchinsky Peter	2305 Beneficiary of a trust
Kolchinsky Anna Inge Leonore Haas	2202 Interest of your spouse
Ra Capital Healthcare Fund, L.p.	2101 Beneficial owner
Ra Capital Healthcare Fund Gp, Llc	2201 Interest of corporation controlled by you
Fu Wei	2307 Founder of a discretionary trust who can infl
Janchor Partners Limited	2102 Investment manager
C-bridge Capital Gp, Ltd.	2501 Other
Vistra Trust (singapore) Pte. Limited	2501 Other
C-bridge Capital Gp Iv, Ltd.	2201 Interest of corporation controlled by you
C-bridge Iv Investment Nine Limited	2101 Beneficial owner

Everest Medicines (HKSE:01952) Headlines

No Headlines